1. Home
  2. CVM vs SABS Comparison

CVM vs SABS Comparison

Compare CVM & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CVM
  • SABS
  • Stock Information
  • Founded
  • CVM 1983
  • SABS 2014
  • Country
  • CVM United States
  • SABS United States
  • Employees
  • CVM N/A
  • SABS N/A
  • Industry
  • CVM Biotechnology: Biological Products (No Diagnostic Substances)
  • SABS Biotechnology: Pharmaceutical Preparations
  • Sector
  • CVM Health Care
  • SABS Health Care
  • Exchange
  • CVM Nasdaq
  • SABS Nasdaq
  • Market Cap
  • CVM 40.1M
  • SABS 32.1M
  • IPO Year
  • CVM 1987
  • SABS N/A
  • Fundamental
  • Price
  • CVM $0.40
  • SABS $3.53
  • Analyst Decision
  • CVM
  • SABS Strong Buy
  • Analyst Count
  • CVM 0
  • SABS 5
  • Target Price
  • CVM N/A
  • SABS $12.40
  • AVG Volume (30 Days)
  • CVM 2.0M
  • SABS 69.6K
  • Earning Date
  • CVM 01-13-2025
  • SABS 11-06-2024
  • Dividend Yield
  • CVM N/A
  • SABS N/A
  • EPS Growth
  • CVM N/A
  • SABS N/A
  • EPS
  • CVM N/A
  • SABS N/A
  • Revenue
  • CVM N/A
  • SABS $1,512,723.00
  • Revenue This Year
  • CVM N/A
  • SABS N/A
  • Revenue Next Year
  • CVM $152.91
  • SABS N/A
  • P/E Ratio
  • CVM N/A
  • SABS N/A
  • Revenue Growth
  • CVM N/A
  • SABS N/A
  • 52 Week Low
  • CVM $0.36
  • SABS $2.16
  • 52 Week High
  • CVM $3.08
  • SABS $6.30
  • Technical
  • Relative Strength Index (RSI)
  • CVM 38.00
  • SABS 46.39
  • Support Level
  • CVM $0.37
  • SABS $3.50
  • Resistance Level
  • CVM $0.42
  • SABS $4.35
  • Average True Range (ATR)
  • CVM 0.04
  • SABS 0.41
  • MACD
  • CVM -0.00
  • SABS -0.07
  • Stochastic Oscillator
  • CVM 11.83
  • SABS 19.22

About CVM Cel-Sci Corporation

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: